Andecaliximab - Gilead Sciences

Drug Profile

Andecaliximab - Gilead Sciences

Alternative Names: Anti-matrix metalloproteinase-9 monoclonal antibody; Anti-MMP9 monoclonal antibody; GS-5745; MMP9 mAb inhibitor

Latest Information Update: 12 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences
  • Class Antineoplastics; Antiulcers; Monoclonal antibodies
  • Mechanism of Action Matrix metalloproteinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gastric cancer
  • Phase I Solid tumours
  • Discontinued Chronic obstructive pulmonary disease; Crohn's disease; Cystic fibrosis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 01 Jun 2018 Efficacy and adverse events data from a phase Ib trial in Solid tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 27 Feb 2018 Gilead Sciences has patent protection for andecaliximab in USA
  • 27 Feb 2018 Gilead has patents pending for andecaliximab in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top